ST1 IMMUNOTOXIN TREATMENT FOR PREVENTION OF GVHD

ST1 免疫毒素治疗预防 GVHD

• 批准号: 3888104
• 负责人: JOSEPH ANTIN
• 金额: --
• 依托单位: BRIGHAM AND WOMEN'S HOSPITAL
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3888104
• 关键词: CD antigens; T lymphocyte; graft versus host disease; human subject; human therapy evaluation; immunoconjugates; immunotherapy; monoclonal antibody

This is a phase I/II trial of the use of monoclonal F(AB)2 fragment conjugated to the A chain of ricin. The monoclonal antibody recognizes the CD5 cell surface protein. T cells that are CD+5 internalize the immunotoxin and are killed, thus reducing the number of infused T cells and reducing the risk of GVHD> The therapy for rate of engraftment and rate of development of graft versus host disease is being assessed.

这是使用单克隆F（AB）2片段使用的I/II期试验 结合了ricin链。 单克隆抗体识别 CD5细胞表面蛋白。 CD+5的T细胞内部化 免疫毒素并被杀死，从而减少了注入的T细胞的数量 并降低GVHD的风险>植入率和 正在评估移植物与宿主疾病的发育率。